# A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

> **NCT06816017** · PHASE1 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Eciskafusp Alfa
- **DRUG:** BCG Medac Strain

## Key facts

- **NCT ID:** NCT06816017
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-15
- **Primary completion:** 2028-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decision of the Sponsor.
- **Last updated:** 2025-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816017, "A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06816017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*